SteadyMed (NSDQ:STDY) said yesterday that it finished a clinical study for its lead drug candidate, Trevyent. The pulmonary arterial hypertension treatment is a combination of treprostinil and the PatchPump prefilled, disposable infusion system.
The San Ramon, Calif.-based company said it is on track to submit a New Drug Application for Trevyent in the 2nd quarter of 2017.
Get the full story at our sister site, Drug Delivery Business News.